Zimbabwe has rejected a substantial US health deal valued at $367m (£272m) spanning five years due to Washington's demand for sensitive information.
This rejection came to light following a official document dated December was leaked, indicating that President Emmerson Mnangagwa believed the deal was "lopsided".
An official spokesman later clarified that the US was requesting biological samples for research and profit while refused to share the benefits from future medical innovations.
"We must now begin the difficult and regrettable task of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had furnished more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for continued negotiations to secure a agreement acceptable to all parties so the country's critical HIV programme can proceed.
Wider Background
Zimbabwe's decision comes after a comparable situation in neighbouring Kenya, where a high court halted a similar health funding agreement following concerns were raised about the safety of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
The agency had managed assistance for the American government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral deals to enhance transparency and responsibility.
Based on reports, 16 African countries have to date signed these new health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration could have provided extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"Our nation was requested to surrender its genetic material and health information for a long time, with no corresponding promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Put simply, our country would supply the basic resources for medical research with no assurance that the resulting innovations would be available to our population if a new disease outbreak arise."
Sovereignty and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending structures already set up via the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to deal with potential pandemics.
"This system is intended to ensure that when a country provides its information, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the resources to create them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage continued discussions with our US partners on how future collaboration could be structured in a way that respects the independence and interests of each country."
Medical Community Reaction
A leading public health body expressed it recognised the government's concerns, but recommended that talks need to persist given that much of the country's Aids initiatives were funded by external financing.
"If technical issues exist, such as those relating to data governance or agreement terms, these can frequently be addressed via technical clarification and negotiated safeguards," the group added.
The situation highlights the continuing debate between receiving crucial international aid and protecting local interests in an ever more data-driven world.